Silence Therapeutics plc develops siRNA therapies through its proprietary mRNAi GOLD platform and trades in the U.S. through American Depositary Shares under SLN. Company news commonly covers clinical and preclinical updates for RNA-silencing programs in cardiovascular disease, hematology and rare diseases, along with financial results, research presentations and collaboration activity.
Recurring pipeline coverage centers on divesiran, a wholly owned siRNA candidate targeting TMPRSS6 for polycythemia vera, including SANRECO study updates and its FDA Fast Track and Orphan Drug designations. Updates also address platform-derived programs such as SLN312, AstraZeneca collaboration matters, balance-sheet commentary and board or executive changes.
Silence Therapeutics has commenced dosing in the Phase I clinical trial of SLN360, targeting cardiovascular disease linked to elevated lipoprotein(a) levels. The APOLLO trial aims to assess the safety, tolerability, and pharmacokinetics of SLN360 in approximately 88 participants with Lp(a) levels ≥60 mg/dL. Results from the initial dosing phase are expected later this year. SLN360, a gene silencing therapy, seeks to lower elevated Lp(a) and reduce associated heart disease risks.
Silence Therapeutics plc announced an oversubscribed private placement of 2,022,218 American Depositary Shares (ADSs) at $22.50 per share, raising approximately $45 million. The funds will primarily support the development of Silence's messenger RNAi GOLD™ platform and general corporate purposes. The placement is expected to close on February 9, 2021, with new shares representing 6.8% of the company's issued share capital. The firm plans to register the ADSs with the SEC for resale. Notably, Silence anticipates releasing clinical data from its mRNAi GOLD™ platform in the first half of 2021.
Silence Therapeutics has appointed Michael H. Davidson, MD, a lipidology expert, to its Board of Directors to bolster its development of SLN360, aimed at treating cardiovascular diseases. Dr. Davidson brings over 30 years of experience in clinical trials and has a notable history of founding and leading successful biotech companies, enhancing the expertise within Silence's pipeline. This strategic addition is expected to provide valuable insights as Silence advances its GalNAc siRNA platform and prepares for clinical progress with SLN360.
Silence Therapeutics has appointed Craig Tooman as its new Chief Financial Officer effective immediately. Tooman brings over 30 years of biopharmaceutical experience, including roles as CFO at Vyome Therapeutics and Aratana Therapeutics. His expertise in financial strategies and business development is expected to strengthen Silence's position in the RNAi market, especially as the company advances clinical candidates SLN360 and SLN124. CEO Mark Rothera emphasized the strategic timing of this appointment amid significant growth opportunities for the firm.
Silence Therapeutics (AIM: SLN, Nasdaq: SLN) announced its participation in two upcoming virtual U.S. investor conferences. The presentations will include a fireside chat at the H.C. Wainwright BioConnect 2021 Conference on January 11, 2021, at 6:00 a.m. EST, and at the ICR Conference 2021 on January 14, 2021, from 8:30-9:10 a.m. EST. Live webcasts can be accessed on the company's website, with archived replays available for 60 days post-event.
Silence is focused on siRNA therapeutics for significant unmet medical needs.
Silence Therapeutics presented positive pre-clinical data for SLN360 at the American Heart Association's 2020 conference. The data reveals no adverse effects, demonstrating safe biodistribution primarily in the liver and kidneys. SLN360 targets elevated lipoprotein(a), a genetic risk factor for cardiovascular diseases, and is set to enter in-human testing following promising results. The ongoing Phase I APOLLO trial aims to assess safety and efficacy in patients with elevated Lp(a) levels, potentially offering a novel treatment for this unmet medical need.
Silence Therapeutics (AIM:SLN, Nasdaq:SLN) has announced a significant change in its executive leadership, initiating a search for a U.S.-based Chief Financial Officer (CFO). Current CFO Rob Quinn will transition from the role in January 2021 to pursue a new opportunity. This change follows Silence's recent Nasdaq listing aimed at enhancing its U.S. market presence and engagements with investors. Mark Rothera, the CEO, emphasized this strategy to leverage U.S. growth potential, and Iain Ross, the Chairman, acknowledged the strong position left by Quinn.